There are currently no positron emission tomography (PET) radiotracers for the GluN2B (NR2B) binding sites of brain N-methyl-D-aspartate (NMDA) receptors. In rats, the GluN2B antagonist Ro25-6981 reduced the binding of N-((5-(4-fluoro-2-[C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamin ([C]HACH242). This paper reports the evaluation of [C]HACH242 PET in non-human primates at baseline and following administration of the GluN2B negative allosteric modulator radiprodil.
Evaluation of the Novel PET Tracer [C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates.
CHDR
van der Aart J, Yaqub M, Kooijman EJM, Bakker J, Langermans JAM, Schuit RC, Hofman MBM, Christiaans JAM, Lammertsma AA, Windhorst AD, van Berckel BNM
![Evaluation of the Novel PET Tracer [C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates. — CHDR](/media/images/logo.svg){kind=logo}
![Evaluation of the Novel PET Tracer [C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates. — CHDR](/media/images/logo-alt.svg){kind=logo}